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Gene expression analysis of a murine model with
pulmonary vascular remodeling compared to
end-stage IPAH lungs
Kayoko Shimodaira1,2, Yoichiro Okubo1, Eri Ochiai3,4, Haruo Nakayama1, Harutaka Katano5, Megumi Wakayama1*,
Minoru Shinozaki1, Takao Ishiwatari1, Daisuke Sasai1, Naobumi Tochigi1, Tetsuo Nemoto1, Tsutomu Saji2,
Katsuhiko Kamei3 and Kazutoshi Shibuya1,6
Abstract
Background: Idiopathic pulmonary arterial hypertension (IPAH) continues to be one of the most serious intractable
diseases that might start with activation of several triggers representing the genetic susceptibility of a patient. To
elucidate what essentially contributes to the onset and progression of IPAH, we investigated factors playing an
important role in IPAH by searching discrepant or controversial expression patterns between our murine model and
those previously published for human IPAH. We employed the mouse model, which induced muscularization of
pulmonary artery leading to hypertension by repeated intratracheal injection of Stachybotrys chartarum, a member
of nonpathogenic and ubiquitous fungus in our envelopment.
Methods: Microarray assays with ontology and pathway analyses were performed with the lungs of mice. A
comparison was made of the expression patterns of biological pathways between our model and those published
for IPAH.
Results: Some pathways in our model showed the same expression patterns in IPAH, which included bone
morphogenetic protein (BMP) signaling with down-regulation of BMP receptor type 2, activin-like kinase type 1, and
endoglin. On the other hand, both Wnt/planar cell polarity (PCP) signaling and its downstream Rho/ROCK signaling
were found alone to be activated in IPAH and not in our model.
Conclusions: Activation of Wnt/PCP signaling, in upstream positions of the pathway, found alone in lungs from
end stage IPAH may play essential roles in the pathogenesis of the disease.
Keywords: Pulmonary Vascular Remodeling, Stachybotrys chartarum, BMP signaling, BMPR2, PCP pathway
Background
Pulmonary hypertension is a hemodynamic state charac-
terized by elevation of the mean pulmonary arterial pres-
sure leading to right ventricular (RV) failure and
premature death. Pulmonary arterial hypertension
(PAH) affects the small muscular arteries and arterioles
in the lung and is histologically characterized by endo-
thelial and smooth muscle cell proliferation, medial
thickening, and thrombosis in situ. Idiopathic pulmonary
arterial hypertension (IPAH), one of 6 subcategories
proposed by Dana Point Classification [1], accounts for
approximately half of PAH cases [2] and up to 40% of
patients with no family history carries mutations in the
bone morphogenetic protein receptor type 2 (BMPR2)
gene [1]. 7% of patients with IPAH has a family history
[3], and about 70% of these have long been recognized
and are usually due to mutations in BMPR2, or much
less commonly, 2 other members of the transforming
growth factor superfamily, activin-like kinase type 1
(ALK1) and endoglin (ENG) [1]. While BMPR2 muta-
tion strongly predisposes to IPAH, only 20% of mutation
carriers develop a clinical disease [4]. This finding sug-
gests that the development of IPAH first requires a gen-
etic susceptibility, followed by one or several secondary
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triggering factors such as modifier genes and some sort
of stimulus [5]. However, the pathogenesis of IPAH
remains unclear.
To elucidate the pathophysiology of IPAH, we con-
ducted genome-wide analysis of RNA expression profiles
in lungs obtained from the murine model, which showed
a favorable reproducibility to remodel pulmonary arter-
ies induced by inoculation of Stachybotrys chartarum,
an ubiquitous fungus in the surrounding environment
[6]. This was followed in the study by exploration for
factors playing a significant role in the onset of IPAH by
searching discrepant or controversial expression patterns
between in the model and those in IPAH previously
published.
Methods
Detection of S. genes in the human lung tissue of IPAH
patients and controls by nested polymerase chain
reaction (PCR)
Upon getting the informed consent from patient’s family,
a part of lung tissue obtained at autopsy from 9 children
(under 18 years of age) with IPAH and 9 age-matched
controls for detection of S. DNA in the tissue of human
lung. It had been confirmed that none of them had in-
flammatory changes or other kind of infection in lungs
by histopathological examination before DNA prepar-
ation. This protocol was approved by ethical committee
of Toho University School of Medicine (# 20029). Using
DNA isolated from the lung tissue, nested PCR and gel
electrophoresis were performed in the usual manner.
The following primers were used for identification of S.
gene from autopsied lungs [7,8]: a primary primer of a
two-step nested assay, forward primer S-Chart-tri5-F2-
5 0-TACACCAGGGAGGAGCGTGTT-30 and reverse
primer S-Chart-tri5-R2-50-GCCGACAATGGTTCGAA
GGGA-30 produced a product of 138 bp. For the nested
PCR primers, forward primer S-Chart-tri5-F2n-50-GAAA
ATCTCCAGTATGCCT-30 and reverse primer S-Chart-
tri5-R2n-50-AGCCTCCAGTCTCTTGGGG-30 produced a
product of 96 bp. For β-actin, the control for DNA quality,
a two-step nested assay was also used with the following
primers: forward primer B3-50-ACACAACTGTGTT
CACTAGC-30 and reverse primer B4-50-CAACTTCATC
CACGTTCACC-30 produced a product of 110 bp. For the
nested PCR primers, forward primer b-globin-nestF34-52-
50-AACCTCAAACAGACACCAT-30 and reverse primer
b-globin-nestR103-85-50-TTGCCCCACAGGGCAGTAA-
30 produced a product of 70 bp. The PCR amplification
was performed as follows: initial denaturation at 94°C for
2 min, followed by 35 cycles of denaturation at 94°C for
30 s, annealing at 55°C for 30 s, with an extension at
72°C for 30 s, and a final extension at 72°C for 7 min.
The second-round PCR reactions were performed in a
manner identical to that applied for the first strand PCR,
except for using different sets of primers. The PCR pro-
ducts were analyzed by electrophoresis on an agarose gel
stained with ethidium bromide upon preparation.
Fungal preparation and intratracheal injection
S. chartarum (IFM 53637), which produces trichothe-
cene mycotoxins, was isolated from house dust in Japan,
and has been stored in the culture collection of the
Medical Mycology Research Center, Chiba University.
The fungus was grown on potato dextrose agar (PDA)
slants for 3 weeks at 25°C. Spores were collected in
RPMI1640 medium (Sigma, St. Louis, MO, USA) and
the concentration was adjusted to 4 × 105 spores / ml.
Spore concentrations and appearance of the suspension
were evaluated under light microscopy before use. Six-
week-old male ddY mice (Tokyo Laboratory Animals
Science, Tokyo, Japan) were employed in this study.
Mice were lightly anaesthetized with an intraperitoneal
injection of ketamine (65 mg/kg BW) and xylazine
(13 mg/kg BW). Their mean weight was 27.4 ± 1.21 g.
The mice were placed in a supine position and a 24 G
intravascular catheter (Insyte-W; Becton-Dickinson,
Sandy, UT, USA) was then inserted intratracheally. The
spore suspension (25 μl / mouse) containing 1 × 104
spores was injected through the catheter into the trachea
of each mouse 12 times at 4–5 day intervals for 8 weeks
(n = 3) as described previously [6]. Control mice (n = 3)
were injected with the same volume of RPMI-1640
medium rather than the spore suspension. All mice were
cared for in accordance with the rules and regulations
set out by the Prime Minister’s Office of Japan. Animal
protocols were approved by the Special Committee on
Animal Welfare of Chiba University. (DOU: 21–65).
Histopathology and morphometric analysis of pulmonary
arteries
Mice were sacrificed using by an overdose of diethyl
ether inhalation 7 days after the last injection. Lungs
were removed and fixed with a 10% formaldehyde solu-
tion, embedded in paraffin, cut into 3 μm-thick sections,
and stained with hematoxylin and eosin for histopatho-
logical examination. Elastic fiber was stained with
Elastica-van Gieson staining (Muto pure chemicals,
Tokyo, Japan). Morphometric analyses were performed
to determine the luminal stenosis of the pulmonary ar-
teries. At least 200 pulmonary arteries per lung section
from each mouse were chosen at random and examined.
Cross-sections of arteries observed in the section were
used to measure the distance between the external elas-
tic lamina, internal elastic lamina, and intravascular
lumen. All images were analyzed using IMAGE J 1.36b
software (National Institutes of Health, Bethesda, MD,
USA). The stricture rate was therefore calculated.
Morphometry measurements were performed according
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to the techniques described in Dail and Hammar’s Pul-
monary Pathology [9]. The thickness of media was cal-
culated by subtracting the distance between the internal
elastic lamina from that of the external lamina, and the
thickness of the intima was calculated by subtracting the
distance between the intravascular lumen from that of
the internal elastic lamina. The distance between the ex-
ternal elastic lamina of the artery was defined as the
diameter. Arteries were divided into three groups
according to diameter: 50 < μm, 50–100 μm, and
>100 μm. Data are given as mean ± SD. Statistical ana-
lyses were performed using Mann-Whitney's U test. Dif-
ferences were considered significant at P < 0.05.
RNA isolation and quality identification
RNA was isolated from the whole lung homogenates for
both microarray analysis and Real-time (RT) Quantita-
tive PCR with the RNeasy Lipid Tissue Mini Kit (Qiagen,
Alameda, CA, USA) according to the manufacturer’s
instructions and stored at −80°C. Total RNA quality was
assessed and confirmed using the Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, CA, USA) for
visualization of the 28S and 18S rRNA bands. RNA con-
centration and purity were also assessed and confirmed
using the UV spectrophotometer NanoDrop™ND-1000
(NanoDrop Technologies, Wilmington, DE, USA), which
calculates 260/280 ratios.
RNA preparation for microarray analysis
cDNA preparation and microarray analysis were con-
ducted at Bio Matrix Research (Chiba, Japan) using the
Affymetrix system (Santa Clara, CA, USA). Isolated total
RNA (100 μg) was converted into double-stranded
cDNA using 30IVT Express kit (Affymetrix, Santa Clara,
CA, USA), which was purified using a GeneChip Sample
Cleanup Module (Affymetrix, Santa Clara, CA, USA). In
vitro transcription reactions were performed using a
GeneChip IVT Labeling Kit, which includes T7 RNA
polymerase and biotin-labeled ribonucleotides. Biotin-
labeled cRNA was purified using a GeneChip Sample
Cleanup Module. The concentration of cRNA was calcu-
lated from light absorbance at 260 nm using a UV spec-
trophotometer. cRNA (15 mg) was then fragmented at
94°C in the presence of a fragmentation buffer (Affyme-
trix, Santa Clara, CA, USA). The labeled cRNA was
purified, fragmented, and spiked with in vitro transcrip-
tion controls.
Microarray analysis
Mouse Genome 430 2.0 microarrays (Affymetrix, Santa
Clara, CA, USA) were hybridized with 12.5 μg of cRNA.
The array was incubated for 16 hr at 45°C, and automat-
ically washed and stained with the GeneChip
Hybridization, Wash and Stain Kit (Affymetrix, Santa
Clara, CA, USA) on an Affymetrix GeneChip Fluidics
station. The arrays were analyzed using the GeneChip
Scanner 3000. All preparations were run on quality-
controlled chips and had 30/50 signal ratios of less than 3.
The expression value of the transcript was computed
using Affymetrix® GeneChip® Command Console®
Software (AGCC) with the MAS5 algorithm [10], in
which the probabilities of the values of each transcript
were indicated as the “Flag” Present (p ≼0 to <0.04),
Marginal (p ≼0.04 to <0.06), and Absent (p ≼ 0.06 to
<0.5). Further analysis was performed with probes that
had a present call in all analyzed samples. For analysis,
the data were normalized using GeneSpring® GX 10.0
(Agilent Technologies, Palo Alto, CA, USA) data-mining
software, per-chip normalization to the 50th percentile
of the measurements for the array, and per-gene by nor-
malizing to the median measurement for the gene across
all the arrays in the data set. In addition, fold changes
were calculated by this software for each gene between
the experimental groups and controls. Statistically sig-
nificant differences were investigated by means of un-
paired t-tests. Gene expression differences with p < 0.05
and at least a ±1.3-fold change were considered statisti-
cally significant. We employed the Biological Networks
Gene Ontology (GO) tool BINGO [11] (http://www.psb.
ugent.be/cbd/papers/BiNGO) to find statistically over-
or under-represented GO categories in biologic data as
the tool for GO analysis of the stored genes. The analysis
was done using the ‘hyper geometric test’, and all GO
biological process terms that were significant with
P < 0.05 (after correcting for multiple term testing using
Benjamin and Hochberg false discovery rate corrections)
were selected as over-represented and under-represented.
Furthermore, the open access and curated pathway
database REACTOME [12] (http://www.reactome.org)
was used to determine which events (reactions and/or
pathways) were statistically overrepresented in a set
of genes.
RT Quantitative PCR for evaluating the microarray results
cDNA preparation and RT-PCR were performed at Bio
Matrix Research (Chiba, Japan). 2 μg of isolated RNA
was used for cDNA synthesis (40 μl) using a Superscript
III First Strand Synthesis System (Invitrogen, Carlsbad,
CA, USA). To evaluate the concentration and purity of
cDNA, 260/280 ratios were calculated using the UV
spectrophotometer NanoDrop™ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA). PCR was per-
formed in a 15 μl reaction mixture containing 1 μl of
sample cDNA, 0.75 μl of TaqMan® Gene Expression
Assays, 7.50 μl of TaqMan Universal PCR Master Mix,
and 5.75 μl of RNase / DNase free water (Applied Bio-
systems, Foster City, CA, USA). 15 μl of PCR reaction
mix was transferred into a 384-well reaction plate. The
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primer sequences are given in Table 1. Gene expression
was measured on a 7900HT Fast RT-PCR system (Ap-
plied Biosystems, Foster City, CA, USA) with cycle con-
ditions of 50°C/2 min, 95°C/10 min, 95°C/15 sec, and
60°C/1 min (steps 3–4 were repeated 40 times). Assay
results were collected and analyzed using SDS 2.2 soft-
ware (Applied Biosystems, Foster City, CA, USA). Each
value is the mean of three biological replicates. Data are
given as mean ± SD. Statistical analyses were performed
by non-paired t-tests. Differences were considered sig-
nificant at P < 0.05.
Literature search concerning gene expression pattern in
IPAH
We used PubMed (http://www.ncbi.nlm.nih.gov/pubmed/)
to search for previous studies published since 2000 that
analyzed biological molecules with altered expression using
lung samples isolated from IPAH, compared with normal
control or secondary PAH. From microarray studies, we re-
ferred to open access data stored in Gene Expression
Omnibus: GEO (http://www.ncbi.nlm.nih.gov/geo/) and
identified the genes that were differentially expressed fol-
lowing the methods described in each study. GO and
Pathway analysis were performed on the genes in the
same way as we done on our data.
Comparing expression patterns of molecules between
IPAH and experimental model
The biological molecules reported in various studies
were collected and divided into groups according to the
gene ontology biological process and pathways using the
Gene Ontology Annotation Database GOA [13] (http://
www.ebi.ac.uk/GOA/), REACTOME [12], and KEGG
[14] (http://www.genome.jp/kegg/). The expression pat-
tern of each group in IPAH was compared with our
PAH models.
Results
Detection of S. genes in human lung tissue from patients
with IPAH and controls by nested PCR
S. chartarum DNA was detected in 6 of 9 lung samples
among both two groups, children with IPAH and age-
matched controls (Figure 1). There was no difference in
the frequency (approximately 70%) of the detection in
children, with or without of IPAH.
Pathological findings in experimental PAH
Diffuse symmetric thickening of intima and media in the
pulmonary artery was shown in the experimental group
(Figure 2). The thickened intima and media were accom-
panied by proliferation of myointimal and smooth
muscle cells, respectively. None of arteries showed
alterations corresponding to necrosis, thrombosis, and
plexiform lesions. The changes developed in arteries of
small and medium-sized were mostly uniform. The
thickened intima and media were statistically significant
regardless of the size of vessels (Figure 3).
In this model, no venous canals were altered. None
were found of components from injected fungus (spores
and hyphae) and changes likely induced by the injection,
such as perivascular cuffing and intraalveolar inflamma-
tory exudates.
Table 1 Primers used in RT-PCR
Gene Symbol Assay ID* RefSeq† Context Sequence
Acvrl1 Mm03053695_s1 NM_009612.2 TTTGTGGGAGCACTTGGCCTGTGAC
Bmpr2 Mm01254942_m1 NM_007561.3 AGTATACAGATAGGTGAGTCAACAC
Ccl8 Mm01297184_g1 NM_021443.2 CCATGGAAGCTGTGGTTTTCCAGAC
Ccl9 Mm00441260_m1 NM_011338.2 AGATCACACATGCAACAGAGACAAA
Ear11 Mm00519056_s1 NM_053113.2 CACAACTCCGGCCAGTCATTATTCC
Eng Mm00468256_m1 NM_001146348.1 AAAAAACACGTGCAGACTCTCCAGT
Gapdh‡ Mm99999915_g1 NM_008084.2 TGAACGGATTTGGCCGTATTGGGCG
Igj Mm00461780_m1 NM_152839.2 TCCGAATTGTTGTCCCTTTGAACAA
Mmp12 Mm00500554_m1 NM_008605.3 AAGTTTTCAAGGCACAAACCTCTTC
Mmp13 Mm00439495_g1 NM_008607.1 GAACCACGTGTGGAGTTATGATGAT
Mmp19 Mm00491300_m1 NM_021412.1 TGGTGCTGGGGCCTCGTGGGAAGAC
Nos3 Mm01134921_g1 NM_008713.4 CGGCGTGCTGCGGGATCAGCAACGC
Pdgfa Mm01205760_m1 NM_008808.3 GGAGGAGGAGACAGATGTGAGGTGA
Vegfa Mm01281449_m1 NM_001025250.3 ACGTACTTGCAGATGTGACAAGCCA
*Taqman® Gene Expression Assays.
†NCBI Gene Reference: NCBI transcript ID detected by the assay.
‡GAPDH: Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control.
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Gene expression in the PAH model mouse
Upon normalizing the expression values for the samples,
the scatter plot of log intensity values was obtained as
shown in Figure 4. 337 and 503 genes were found to ex-
hibit up- and down-regulation from the lungs of mice
with inoculation of the fungus in comparison to those
from the control group. The most markedly up- and
down- regulated genes are shown in Table 2. Down
regulation of BMPR2, ALK1, and ENG was found in our
PAH model. Down regulation of SMAD family member
6 expression was also observed, while the expressions of
other genes involved in bone morphogenetic protein
(BMP) signaling were unchanged. All the microarray
data are MIAME compliant and the complete micro-
array data were deposited in GEO (accession number
GSE23178). 696 biological process terms were detected
by GO analysis in up-regulated genes. GO terms related
to the immune system and cytokines accounted for
about 80% of total terms. Among the remaining terms,
estrogen receptor signaling pathway and serotonin trans-
port/secretion were included. A statistically significant
biological process was not found for down-regulated
genes. Pathway analysis revealed that reactions and path-
ways related to the immune system, Janus kinase/signal
transducers and activators of the transcription (JAK/
STAT) pathway, and hemostasis etc. were detected
(Table 3) in up-regulated genes. Additionally, vascular
endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), apoptosis, BMP signaling, etc.
were detected in down-regulated genes.
Validation of microarray results by RT quantitative PCR
analysis
RT-PCR was used to validate 14 selected genes that were
induced or suppressed by the exposure. The correlation
of fold changes in gene expression between the arrays
and PCR is shown in Table 4. The results demonstrate
completely the same gene expression pattern between
both methods. The alterations of gene expressions were
statistically significant in BMPR2, ENG, Vascular endo-
thelial growth factor A, Platelet-derived growth factor
alpha polypeptide, matrix metallopeptidase (MMP) 19,
MMP12, eosinophil-associated ribonuclease A family
member 11, and chemokine ligand 9.
Altered expression of biological molecules and genes in
lungs from IPAH
The biological molecules reported in previous studies
[15-28] were listed in Additional file 1. Microarray data
of patients with IPAH and normal controls were refer-
able from 3 individual studies [15,16,27]. The numbers
of IPAH investigated in each study were 2 [16], 7 [27],
and 18 [15], the mean age and its standard deviation
were 44 ± 10 [16], 29 ± 16 [27], and 44 ± 18 [15], respect-
ively. We analyzed the microarray data in each study
and tried to extract the genes that showed common ex-
pression patterns through these three studies. However,
there were few genes, and none of significant GO or
pathways was identified among the previous reports
regarding to IPAH.
Comparing expression patterns of molecules between
IPAH and experimental model
Events (reactions and/or pathways) and the expression
patterns in IPAH extracted from the previous reports
are listed with comparison to those resulted from our
experimental model [15-28] (Table 5).
Discussion
Since PAH is a progressive disease of unknown cause in-
volving pulmonary arterial remodeling, characterized by
relentless deterioration and death, intense investigations
Figure 1 Detection of Stachybotrys chartarum gene in the human lung tissue of IPAH patients and controls. Agarose gel electrophoresis
showed the amplification products after nested polymerase chain reaction for S. chartarum DNA using the standard assay. P1- P2: Positive control
(96 bp and 70 bp); S1-S9: Children with IPAH; C1-C9: Age-matched control; N: Negative control (No DNA). S. chartarum and β-globin bands are 96
and 70 bp, respectively. 96 bp–specific band was detectable in P1-2, S1-2, S4, S6, S8-9, C1, C3-4, C6, C8-9.
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have been conducted in a variety of animal models [29]
to know pathophysiology. The most commonly used
were rats exposed to either hypoxia or monocrotaline,
and newer models were introduced that involved modifi-
cation of these approaches using rodents including
transgenic mice [29,30].There were at least three geno-
mewide studies conducting rat models among them, but
little have been discussed with comparison to those in
the human disease with pathway and GO analyses [31-33].
We have therefore aimed to elucidate a part of patho-
physiology of PAH accompanied by pulmonary arterial re-
modeling with comparison in gene expression pattern
between those previously known in end-stage IPAH and
our murine model, of which muscularization in media and
intima of pulmonary arteries was induced by inoculation
of nonpathogenic fungus [6,34]. It was found that a large
frequency of S. chartarum gene in the lung of both
children with IPAH and age-matched controls in autopsy
cases, whereas the prior histological examination had
revealed no inflammatory changes with an association to
fungal infection. The result suggests that the airway of
human generally exposed by the ubiquitous fungus.
Accordingly, unknown intrinsic factors may play a
significant role in the onset of IPAH.
It was explored in the study to search the pathways
which show common expression pattern among IPAH
patients using microarray data previously published as
well as up-loaded at the open access sites [15,16,27], but
Figure 2 Pulmonary vascular remodeling in Stachybotrys chartarum-exposed mice. Peripheral pulmonary arteries in experimental group
(A, C, and E) and control group (B, D, and F). A and B: hematoxylin and eosin double stain, C, D, E, and F: Elastic Van Gieson stain. (A) Pulmonary
vascular thickening was present over the whole lung. (C) The arterial wall shows symmetrical thickening of the intima and media. (E) This vascular
remodeling almost totally obliterates the lumens. (B, D, and F) Structure of the lung from control group is unaltered. Scale bars: 500 μm (A, B),
250 μm (C, D), and 50 μm (E, F).
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none were elucidated. A part of the result may reflect
clinical differences in subjects such as age, gender, stage
of the disease, and etc. On the other hand, the present
murine model showed similar expression pattern of
genes which has been generally accepted as some bio-
logical molecules associated with the pathogenesis of
IPAH, such as BMP signaling [1,35,36]: BMPR2, ALK1,
and ENG. Although some of previous genome-wide ana-
lyses [31-33] conducting rat models reported alterations
of signaling pathway (Table 6), the present model
revealed more favorable similarity in number of path-
ways expressing same manner to IPAH. However, the re-
sult from our study might be affected by recruited
cellular components and/or reformed extracellular
matrix, because RNA was extracted from the whole lung
of the mice. Although RNA extraction was done one
week after the latest inoculation of the fungus when no
inflammatory change had been previously confirmed [6],
in vitro work evaluating cells from the lungs of the mice
would be required to look at functional alterations. In
addition, whereas multiple time point’s evaluation could
highlight the difference in pathophysiology of models of
between our mice and rats previously published, we have
evaluated once at the point when the most significant
muscularization had been confirmed [6], since a priority
in the study would have been set in comparing gene ex-
pression patterns between end-stage IPAH and our
model. It has been generally accepted that the altered
expression of BMP signaling was one of the important
molecular reactions when pulmonary vascular remodel-
ing developed as the response to some sort of stimulus
[2,3]. This can be supported by the facts that only a few
cases of BMPR2 mutation carriers developed clinical dis-
ease [4] and BMPR2-knockdown mice did not develop
pulmonary artery medial hypertrophy, spontaneously
[29]. Since remodeling of pulmonary artery in our model
may be a sequel to inoculation of nonpathogenic fungus,
down regulation of BMPR2 signaling should be simply
understood as a consequence of muscularization which
might be induced by alteration of signaling pathways at
the upper stream. Besides BMP signaling, four more
pathways known as identical expression patterns in
IPAH were found in our PAH model. It has been sug-
gested that inflammation might participate in the onset
and propagation of pulmonary vascular remodeling in
PAH via the JAK/STAT pathway [37,38], because ele-
vated levels of inflammatory cytokines could trigger in-
flammation that is characteristic of PAH of both
connective tissue disease-associated [39] and Virus-
associated [40]. While PAH is up to threefold more
prevalent in women than men [41], the increased
Figure 3 Morphometric analysis evaluating luminal stenosis of
pulmonary arteries. Significant thickening of both intima and
media were observed in the exposure group when compared with
the control regardless of the size of vessels. Data are presented as
means with standard error of the means. Statistical analyses were
performed using Mann-Whitney's U test. A bar with ** is significantly
different (P < 0.01).
Figure 4 Scatter plot of microarray dataset. Gene expression
signal of control group (Y-axis) plotted against experimental
group (X-axis). The expression data are the average of three
independent gene chips for each group.
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expression of molecules associated with the estrogen sig-
naling pathway are reported in both genders of patients
with IPAH [15]. In addition, the evidence implicating
serotonin has been discussed with correlation to the
anorexigenic drugs aminorex and fenfluramine [42]. As
with alteration of BMP signaling, the altered expression
of these pathways would be simply associated with the
consequence of pulmonary vascular remodeling devel-
oped as the response to some sort of stimulus. It might
be better to understand as a sequel to vascular remodel-
ing because that coagulation activity could be activated
by various stimuli such as a cytokine and endothelial
dysfunction [43].
On the other hand, it emerged that some discrepant
gene expression patterns between those previously
known in IPAH and our model. Four pathways were
identified as those altered alone in IPAH which com-
prised up-regulations of the Wnt/planar cell polarity
(PCP) signaling pathway [27], the Ras homolog (Rho)/
Table 2 The top 10 most up-regulated and down-
regulated genes
Fold-Change* Gene Symbol Description
[Up-regulated Genes]
72.4 Ear11 Eosinophil-associated,
ribonuclease A family, member 11
46.1 Mmp12 Matrix metallopeptidase 12
11.5 Rgs1 Regulator of G-protein signaling 1
11.4 Ccl9 Chemokine ligand 9
10.3 Ccl8 Chemokine ligand 8
10.0 Igj Immunoglobulin joining chain
9.0 Igf1 Insulin-like growth factor 1
8.2 Gpnmb Glycoprotein nmb
8.2 Ccl11 Chemokine ligand 11
8.2 Ccl22 Chemokine ligand 22
[Down-regulated Genes]
4.2 Bex2 Brain expressed X-linked 2
3.1 Upk3b Uroplakin 3B
2.9 Rrm2b Ribonucleotide reductase M2 B
2.7 Lgals2 Lectin, galactoside-binding, soluble, 2
2.7 Acaa1b Acetyl-Coenzyme A acyltransferase 1B
2.3 Shisa2 Shisa homolog 2
2.2 Ssr1 Signal sequence receptor, alpha
2.2 Kcnip4 Kv channel interacting protein 4
2.2 Msln Mesothelin
2.1 Fam82b Family with sequence
similarity 82 member
2.1 Upk1b Uroplakin 1B
2.1 Vldlr Very low density lipoprotein receptor
*Fold change values are calculated by dividing the experimental group values
by the control values.
Table 3 Events (reactions and/or pathways) associated
with up-regulated and down-regulated genes
Event ID* Event Name† P value Input
Genes in
Event‡
Total
No. of
Genes§
[Up-regulated Genes]
98458 Immune System 1.5e-04 24 478
86456 Integrin alpha X
beta 2 binds JAM-C
7.2e-03 2 6
108524 GPCR ligand binding 3.0e-02 13 322
104591 Eicosanoid
ligand-binding receptors
3.8e-02 2 13
23802 Mouse JAK2 binds human
common beta chain
5.1e-04 2 2
89750 Hemostasis 1.5e-03 19 400
33150 Endogenous sterols 3.4e-02 2 13
108993 Vitamin B2 metabolism 2.9e-03 2 4
111211 Stat5 tyrosine
phosphorylation
4.9e-03 2 5
115537 IL7ra is phosphorylated
on Y449
4.9e-03 2 5
81332 Ubiquitination of
phospho-p27/p21
1.6e-02 2 9
107910 Synthesis, Secretion, and
Deacylation of Ghrelin
2.0e-02 2 10
[Down-regulated Genes]
92778 Axon guidance 3.9e-06 26 353
95727 Myogenesis 4.9e-02 2 13
90528 Signaling by VEGF 4.7e-04 4 14
100071 Integrin cell surface
interactions
7.1e-03 9 123
82568 PDGF binds to extracellular
matrix proteins
3.6e-02 4 45
118126 I-Smad competes with
R-Smad1/5/8 for
type I receptor
1.9e-02 2 8
91050 SOS phosphorylation and
dissociation
7.3e-03 2 5
112933 Cell-Cell communication 1.7e-02 8 118
95483 Metabolism of nitric oxide 3.0e-02 2 10
84093 Ethanol oxidation 1.1e-03 3 8
79841 FMO oxidizes nucleophiles 2.3e-03 2 3
97703 Apoptotic execution phase 1.1e-02 5 49
107112 Aquaporin-mediated transport 8.0e-03 4 29
84730 MAPK targets/ Nuclear events
mediated by MAP kinases
5.0e-02 3 30
*Reactome event accession number.
†Event name according to the Reactome Database.
‡Number of regulated genes in this model.
§Total number of genes involved in the event.
JAM: Junctional adhesion molecule, GPCR: G protein coupled receptors, JAK:
Janus kinase, VEGF: Vascular endothelial growth factor, PDGF: platelet-derived
growth factor, SOS: Son of Sevenless proteins, FMO: Flavin Monooxygenases,
MAPK: mitogen-activated protein kinase, MAP: Mitogen-activated protein.
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Rho- Associated Coiled-Coil-Forming Protein Kinase
(ROCK) pathway [26,27], and the hypoxia response
pathway [23,24], and down-regulations of the transform-
ing growth factor beta (TGFB) signaling pathway [16].
Both PDGF signaling pathway [25] and VEGF signaling
pathway [15,26] were found as those up-regulated in
IPAH and down-regulated in this model. Interestingly,
not detected was a pathway showing the reverse pattern.
Among these various pathways, we would focus on the
Wnt/PCP pathway as the essential pathway of pathogen-
esis in IPAH because this pathway is presently known to
be in the upper levels of hierarchical pathways regulating
other related pathways [12-14]. Laumanns et al. reported
that microarray analysis of lung tissue from patients with
IPAH demonstrated the contribution of this pathway to
the pathogenesis of IPAH [27]. It has been reported Wnt
family of signaling proteins is essential for organ devel-
opment in general, and lung morphogenesis in particular
[44]. Especially, the PCP pathway signals through activa-
tion of the Rho/ROCK signaling pathway are implicated
in cytoskeletal organization and epithelial cell polarity.
In addition, this pathway has been shown to be required
for normal lung development, and reports are beginning
to emerge of links between PCP pathways and lung dis-
ease [45]. Besides IPAH, PCP gene expression changes
were observed within isolated pulmonary vasculature in
patients with pulmonary fibrosis. Studies of patients with
IPAH have shown significant up-regulation of PCP sig-
naling [27] and down-regulation of TGFB signaling [16].
Investigations have also shown inhibition of canonical
Wnt signaling by PCP ligands [45], crosstalk between ca-
nonical Wnt signaling and TGFB signaling [46], and re-
cruitment of both canonical and non-canonical Wnt
pathways are required in BMP2 mediated angiogenesis
in human pulmonary artery endothelial cells [47]. A part
of results from the present study, no change of pathways
around this system can support that altered interaction
between the canonical Wnt pathway and the TGFB sig-
naling pathway play an essential role for human disease
and further clarification is expected of the role of the
PCP pathway in the pathogenesis of IPAH. On the other
hand, some previous reports conducted human disease
reported the Rho/ROCK signaling pathway is also acti-
vated, but it is known that many other stimuli can acti-
vate this system [48]. An activation of this pathway may
conduct to smooth muscle cell proliferation in pulmon-
ary artery [49], we wish to understand this event as sec-
ondary episode to alteration in PCP signaling pathways.
Although, the details in the mechanism is unclear,
various factors (e.g., Hypoxia, inflammation, and shear
Table 4 Quantitative PCR Validation of Microarray
Expression data
Gene symbol Gene Name Fold Change (P value)*
RT-PCR Microarray
Acvrl1 Activin A receptor,
type II-like 1
0.7(0.07) 0.7(0.05)
Bmpr2 Bone morphogenic
protein receptor, type II
0.6(0.04) 0.8(0.04)
Eng Endoglin 0.5(0.05) 0.7(0.05)
Ccl8 Chemokine ligand 8 14.0(0.06) 10.3(0.04)
Ccl9 Chemokine ligand 9 9.5(0.03) 11.4(0.02)
Ear11 Eosinophil-associated,
ribonuclease A family,
member 11
76.0(0.04) 72.4(0.02)
Igj Immunoglobulin
joining chain
20.5(0.26) 10.0(0.05)
Mmp12 Matrix metallopeptidase 12 104.6(0.05) 46.1(0.02)
Mmp13 Matrix metallopeptidase 13 5.1(0.17) 5.7(0.05)
Mmp19 Matrix metallopeptidase 19 3.1(0.05) 2.9(0.05)
Nos3 Nitric oxide synthase 3,
endothelial cell
0.7(0.09) 0.8(0.17)
Pdgfa Platelet derived
growth factor, alpha
0.7(0.01) 0.8(0.07)
Vegfa Vascular endothelial
growth factor A
0.6(<0.01) 0.7(0.04)
Gapdh† Glyceraldehyde-3-phosphate
dehydrogenase
1.0(<0.01) 0.9(0.46)
*Fold change values are calculated by dividing the experimental group values
by the control values. Statistical analyses were performed by non-paired t-tests
†Gapdh was used as an internal control.
Table 5 Events (reactions and/or pathways) and the
expression patterns in IPAH and in our PAH model
ID* Event Name† IPAH‡ Present model
map04630 JAK/STAT signaling Up UP
REACT_604 Hemostasis Up Up
GO:0030520 Estrogen receptor
signaling pathway
Up Up
GO:0007210 Serotonin receptor
signaling pathway
Up Up
GO:0001666 Response to hypoxia Up Not identified
map04310 Wnt/PCP pathway Up Not identified
REACT_19389 ROCK activation by Rho Up Not identified
REACT_16888 Signaling by PDGF Up Down
REACT_12529 Signaling by VEGF Up Down
GO:0042981 Regulation of
apoptotic process
Up/Down Down
REACT_12034 Signaling by BMP Down Down
REACT_6844 Signaling by TGF beta Down Not identified
*Accession number of Reactome, KEGG, and GO.
†Event name according to the Reactome, KEGG, and GO Database.
‡Expression pattern of biological molecules associated with the event in lung
tissue obtained from patients with IPAH in previously published reports
JAK/STAT: Janus kinase-signal transducer and activator of transcription, PCP:
planar cell polarity, ROCK: Ras Homolog- Associated Coiled-Coil-Forming
Protein Kinase, Rho: Ras Homolog, PDGF: Platelet-derived growth factor, VEGF:
Vascular endothelial growth factor, BMP: Bone morphogenetic protein, TGF:
Transforming growth factor.
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stress) are known as the inducer of growth factors such
as VEGF and PDGF [50,51]. Accordingly, their activation
may not be essential because they usually play at the
lower level of hierarchical pathways, which are activated
by many sorts of stimuli.
Conclusion
Discrepancy in gene expression pattern between this
model and the human disease previously reported sug-
gests that activation of Rho/ROCK signaling via Wnt/PCP
signaling plays an essential role in pathogenesis of IPAH.
Additional file
Additional file 1: Expression pattern of biological molecules in lung
tissue obtained from patients with IPAHand related pathways.
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